Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2016

View Archived Issues

Special report: VHIO's Towards Predictive Cancer Models Symposium

Allergan discloses S1P1 ligands

New research alliance to discover novel treatments for severe fibrotic diseases

Biogen reports topline results from SYNERGY study

ALPK3 gene mutations identified in severe pediatric cardiomyopathy

Janssen begins first-in-human study of JNJ-63709178 for relapsed or refractory AML

Orphazyme cleared to begin AIDNPC intervention study of arimoclomol in U.S.

Tanaka Kikinzoku Kogyo develops kit to detect Zika virus in blood

Phase II dose selected for checkpoint inhibitor PDR-001 in first-in-human study

GlaxoSmithKline launches Nucala for bronchial asthma in Japan

Regulus Therapeutics announces phase II results on RG-101

Catabasis reports phase IIa topline data on CAT-2054 in hypercholesterolemia

FDA committee recommends approval of Teva's Vantrela ER

ABBV-399 shows promising antitumor activity for c-Met+ NSCLC

Skyepharma signs feasibility, development and license agreement with Lucideon

Pfizer announces phase II results of tofacitinib citrate

The role of RACK1 protein in development and progression of nasopharyngeal carcinoma

TapImmune exercises option agreement to Mayo Clinic HER2/neu vaccine technology

Novel xenograft models of digestive diseases

Sage Therapeutics reports promising phase I topline results for SAGE-217

Psilocybin shows promise in a feasibility trial as therapy for treatment-resistant depression

Sorrento and 3SBio form joint venture in China

Chiesi completes two pivotal studies of CHF-5993 for COPD

Axumin now available in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...